Boston Scientific Corporation $BSX Stock Purchased by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer B.V. increased its Boston Scientific stake by 8.1% in the third quarter, bringing its holdings to 467,972 shares valued at approximately $20.4 million. Institutional investors and hedge funds collectively own 89.07% of BSX.
• Boston Scientific reported quarterly EPS of $0.86, exceeding the $0.83 consensus estimate, while revenue rose 7.5% year over year to $5.44 billion. Company insiders also purchased 194,522 shares worth about $9.4 million over the past three months.
• BSX shares opened at $41.98, near their 52-week low, despite analysts maintaining a “Moderate Buy” consensus and an average price target of $66.31. Ratings remain largely positive, though some firms have issued hold or cautious views.

Mn Services Vermogensbeheer B.V. boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 467,972 shares of the medical equipment provider's stock after purchasing an additional 34,959 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Boston Scientific were worth $20,427,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in BSX. First Heartland Consultants Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at $521,000. Allen Mooney & Barnes Investment Advisors LLC lifted its stake in Boston Scientific by 5.1% during the 3rd quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 7,824 shares of the medical equipment provider's stock worth $342,000 after acquiring an additional 382 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Boston Scientific by 79.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 51,596 shares of the medical equipment provider's stock worth $2,252,000 after acquiring an additional 22,897 shares in the last quarter. Everhart Financial Group Inc. boosted its holdings in Boston Scientific by 12.5% during the 3rd quarter. Everhart Financial Group Inc. now owns 13,166 shares of the medical equipment provider's stock valued at $575,000 after acquiring an additional 1,460 shares during the period. Finally, Avidian Wealth Enterprises LLC grew its position in Boston Scientific by 372.9% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 31,451 shares of the medical equipment provider's stock valued at $1,373,000 after acquiring an additional 24,801 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.0%

BSX stock opened at $41.98 on Friday. The company's 50 day moving average price is $46.64 and its 200 day moving average price is $50.71. The firm has a market capitalization of $60.83 billion, a price-to-earnings ratio of 16.99, a PEG ratio of 1.00 and a beta of 0.58. Boston Scientific Corporation has a fifty-two week low of $41.38 and a fifty-two week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The firm's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the business's stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig purchased 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of several research reports. Piper Sandler reissued an "overweight" rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Evercore set a $65.00 target price on shares of Boston Scientific in a report on Monday, July 6th. Leerink Partners set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Argus restated a "hold" rating on shares of Boston Scientific in a research note on Friday, July 31st. Twenty-two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $66.31.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer. Management said the new structure, which organizes operations into three segments, is intended to improve efficiency and support continued growth. Investors may view the move as a potential catalyst for better execution. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
• Neutral Sentiment: The restructuring is receiving additional coverage because Fitzgerald will oversee the three-segment operating model, including changes affecting the cardiovascular business. The strategy could create longer-term benefits, but investors will need evidence that it improves growth and margins. Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an “equal weight” rating and later described the shares as “hold.” The rating signals limited near-term conviction rather than a clear bullish or bearish stance. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low during trading, highlighting continued selling pressure and investor concerns despite the announced leadership changes. The stock remains well below its 52-week high, increasing the importance of upcoming execution and earnings results. Boston Scientific Reaches New 1-Year Low
• Negative Sentiment: Citigroup issued a pessimistic forecast for Boston Scientific, adding to the cautious analyst tone around the shares. This offsets some of the potential optimism from the new operating structure. Citigroup Issues Pessimistic Forecast for Boston Scientific

Boston Scientific Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.